

Ravi A Madan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/51250/ravi-a-madan-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155
papers

4,806
citations

38
h-index

65
g-index

167
ext. papers

5,822
ext. citations

6.4
avg, IF

5.49
L-index

#	Paper	IF	Citations
155	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology, The</i> , 2012 , 13, 501-8	21.7	299
154	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 663-74	7.4	249
153	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF β in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018 , 24, 1287-1295	12.9	195
152	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology, The</i> , 2017 , 18, 587-598	21.7	194
151	Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. <i>Clinical Cancer Research</i> , 2011 , 17, 907-17	12.9	188
150	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1001-11	5.9	161
149	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations 2018 , 6, 141		132
148	Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2070-6	2.2	126
147	Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. <i>Clinical Cancer Research</i> , 2008 , 14, 4526-31	12.9	121
146	Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. <i>Oncologist</i> , 2010 , 15, 969-75	5.7	116
145	Immunotherapy of Prostate Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017 , 23, 6764-6770	12.9	108
144	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	104
143	A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 7164-73	12.9	95
142	Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. <i>Cancer Immunology Research</i> , 2014 , 2, 133-41	12.5	93
141	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. <i>Cancer Immunology Research</i> , 2015 , 3, 1248-56	12.5	89
140	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors 2019 , 7, 240		85
139	Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. <i>Blood</i> , 2012 , 120, 3030-8	2.2	81

138	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. <i>Oncotarget</i> , 2016 , 7, 37762-37772	3.3	76
137	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 99-109	12.9	71
136	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 407-18	7.4	71
135	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 225-34	7.4	70
134	Clinical evaluation of TRICOM vector therapeutic cancer vaccines. <i>Seminars in Oncology</i> , 2012 , 39, 296-304	5.5	68
133	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019 , 24, 1259-1269	5.7	67
132	Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 886-92	8.9	64
131	PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 543-54	5.4	60
130	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2015 , 1, 1087-95	13.4	58
129	Enhancing efficacy of therapeutic vaccinations by combination with other modalities. <i>Vaccine</i> , 2007 , 25 Suppl 2, B89-96	4.1	58
128	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody 2017 , 5, 20		57
127	The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1175-84	8.9	57
126	Overcoming chemotherapy resistance in prostate cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 3892-902	12.9	53
125	Therapeutic cancer vaccines. <i>Advances in Cancer Research</i> , 2014 , 121, 67-124	5.9	49
124	Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 197-206	7.4	47
123	A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015 , 116, 546-55	5.6	45
122	Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. <i>Journal of Immunology</i> , 2013 , 190, 6250-8	5.3	45
121	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma 2019 , 7, 269		43

120	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. <i>Clinical Cancer Research</i> , 2017 , 23, 6833-6845	12.9	39
119	Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. <i>Critical Reviews in Immunology</i> , 2007 , 27, 451-62	1.8	39
118	Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2013 , 111, 1269-80	5.6	38
117	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. <i>Journal of Circulating Biomarkers</i> , 2016 , 5, 5	3.3	34
116	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 77-85	3.3	33
115	Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1521-31	7.4	31
114	Samarium-153-EDTMP (Quadramet [®]) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. <i>Oncotarget</i> , 2016 , 7, 69014-69023	3.3	31
113	A Prospective Comparison of F-Sodium Fluoride PET/CT and PSMA-Targeted F-DCFBC PET/CT in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1665-1671	8.9	29
112	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. <i>Oncologist</i> , 2020 , 25, 290-300	5.7	28
111	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2019 , 25, 4933-4944	12.9	27
110	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 19-28	5.4	26
109	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma 2016 , 4, 92		25
108	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016 , 4, 755-65	12.5	25
107	The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. <i>European Urology</i> , 2012 , 61, 639-47	10.2	24
106	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. <i>Oncotarget</i> , 2015 , 6, 31344-59	3.3	24
105	Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2013 , 133, 373-82	7.5	23
104	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. <i>Oncologist</i> , 2020 , 25, 479-e899	5.7	23
103	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 2469-74	4.4	22

102	Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. <i>Thyroid</i> , 2014 , 24, 1223-31	6.2	22
101	PSA-based vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2006 , 5, 199-209	5.2	22
100	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 562-573	9.7	21
99	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer 2020 , 8,		21
98	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in patients with human papillomavirus-associated malignancies 2020 , 8,		21
97	Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 229-37	3.3	20
96	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 1409-18	5.4	20
95	Therapeutic cancer vaccines: the latest advancement in targeted therapy. <i>American Journal of Therapeutics</i> , 2012 , 19, e172-81	1	20
94	Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016 , 118, 590-7	5.6	19
93	Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. <i>Expert Review of Vaccines</i> , 2011 , 10, 141-50	5.2	19
92	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Oncolmunology</i> , 2016 , 5, e1197459	7.2	19
91	Combining immunotherapies for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 694-700	2.8	18
90	Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. <i>Cancer Journal (Sudbury, Mass)</i> , 2013 , 19, 50-8	2.2	17
89	Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. <i>Oncolmunology</i> , 2012 , 1, 1167-1168	7.2	17
88	Immunotherapy in prostate cancer: emerging strategies against a formidable foe. <i>Vaccine</i> , 2011 , 29, 6485-97	4.1	16
87	Recent advances revolutionize treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2013 , 9, 1133-46	3.6	15
86	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2011 , 10, 743-53	5.2	15
85	Combining Vaccines with Conventional Therapies for Cancer. <i>Update on Cancer Therapeutics</i> , 2007 , 2, 33-39		15

84	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 895-901	5.4	15
83	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021 , 80, 746-757	10.2	14
82	Exploiting synergy: immune-based combinations in the treatment of prostate cancer. <i>Frontiers in Oncology</i> , 2014 , 4, 351	5.3	12
81	Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 ,	7.1	12
80	Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 1505-12	7.3	11
79	Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. <i>Southern Medical Journal</i> , 2015 , 108, 224-8	0.6	11
78	Perspectives on the clinical development of immunotherapy in prostate cancer. <i>Asian Journal of Andrology</i> , 2018 , 20, 253-259	2.8	11
77	A case report of multiple primary prostate tumors with differential drug sensitivity. <i>Nature Communications</i> , 2020 , 11, 837	17.4	10
76	Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. <i>Oncologist</i> , 2020 , 25, 560-e1006	5.7	10
75	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. <i>OncolImmunology</i> , 2014 , 3, e28611	7.2	10
74	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) 2021 , 9,		10
73	The evolving role of immunotherapy in prostate cancer. <i>Current Opinion in Oncology</i> , 2016 , 28, 232-40	4.2	10
72	Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of F-DCFPyL PET/CT with Comparison to Multiparametric MRI. <i>Radiology</i> , 2020 , 296, 564-572	20.5	9
71	The current and emerging role of immunotherapy in prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2010 , 8, 10-6	3.3	9
70	Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. <i>Immunotherapy</i> , 2011 , 3, 27-31	3.8	9
69	Vaccines as monotherapy and in combination therapy for prostate cancer. <i>Clinical and Translational Science</i> , 2010 , 3, 116-22	4.9	9
68	A comparison of prostate cancer bone metastases on F-Sodium Fluoride and Prostate Specific Membrane Antigen (F-PSMA) PET/CT: Discordant uptake in the same lesion. <i>Oncotarget</i> , 2018 , 9, 37676-37688	3.2	9
67	Novel immunotherapy combinations for genitourinary cancers. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 253-262	5.4	9

66	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. <i>Oncologist</i> , 2021 , 26, e847-e858	5.7	9
65	Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. <i>Oncologist</i> , 2013 , 18, 821-2	5.7	8
64	Developing immunotherapy strategies in the treatment of prostate cancer. <i>Asian Journal of Urology</i> , 2016 , 3, 278-285	2.7	8
63	Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. <i>American Journal of Roentgenology</i> , 2020 , 214, 105-113 ^{5.4}	5.4	8
62	A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. <i>European Urology Focus</i> , 2018 , 4, 636-638	5.1	8
61	The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global Pandemic. <i>Clinical Cancer Research</i> , 2020 , 26, 4198-4200	12.9	7
60	The immunotherapy revolution in genitourinary malignancies. <i>Immunotherapy</i> , 2020 , 12, 819-831	3.8	7
59	Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer. <i>Oncologist</i> , 2019 , 24, 16-e14	5.7	7
58	Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells. <i>Journal of Circulating Biomarkers</i> , 2015 , 4, 4	3.3	6
57	Angiogenesis inhibition in the treatment of prostate cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009 , 9, 1070-8	2.2	6
56	Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. <i>American Journal of Therapeutics</i> , 2010 , 17, 176-81	1	6
55	Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 181, 113073	3.5	6
54	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 16	5.4	5
53	Metabolic syndrome in prostate cancer: impact on risk and outcomes. <i>Future Oncology</i> , 2016 , 12, 1947-55.6	5.6	5
52	Therapeutic vaccines for prostate cancer: recent advances and future directions. <i>Expert Review of Vaccines</i> , 2016 , 15, 907-14	5.2	5
51	Prostate cancer immunotherapy: the path forward. <i>Current Opinion in Supportive and Palliative Care</i> , 2017 , 11, 225-230	2.6	5
50	Ipilimumab in prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 303-13	5.4	5
49	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 207-207 ^{2.2}	2.2	5

48	Cancer vaccines: current directions and perspectives in prostate cancer. <i>Current Opinion in Molecular Therapeutics</i> , 2009 , 11, 31-6		5
47	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2020 , 11, 490	5.7	5
46	Immunotherapy in genitourinary malignancies. <i>Current Opinion in Urology</i> , 2016 , 26, 501-7	2.8	5
45	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021 , 27, 429-437	12.9	5
44	Abiraterone. Cougar Biotechnology. <i>IDrugs: the Investigational Drugs Journal</i> , 2006 , 9, 49-55		5
43	Prospects for the future of prostate cancer vaccines. <i>Expert Review of Vaccines</i> , 2016 , 15, 271-4	5.2	4
42	Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. <i>International Journal of Cancer</i> , 2014 , 135, 862-70	7.5	4
41	(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 347	9.7	4
40	Disparities in Cancer Care and the Asian American Population. <i>Oncologist</i> , 2021 , 26, 453-460	5.7	4
39	A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e549-e552	3.3	3
38	Evaluating immune responses after sipuleucel-T therapy. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1119-21	4.6	3
37	Moving the goal posts in prostate cancer trials. <i>Lancet Oncology</i> , 2015 , 16, 247-9	21.7	3
36	Integrating Immunotherapies in Prostate Cancer. <i>Current Oncology Reports</i> , 2015 , 17, 45	6.3	3
35	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1769-81	5.4	3
34	Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 43-6	3.3	3
33	Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response. <i>Cancers</i> , 2012 , 4, 1229-46	6.6	3
32	Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature. <i>American Journal of Therapeutics</i> , 2007 , 14, 310-3	1	3
31	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 475-486	3.5	3

30	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021 , 127, 435-444	5.6	3
29	Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. <i>IEEE Access</i> , 2021 , 9, 87531-87542	3.5	3
28	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer 2021 , 9,		3
27	The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 1429-35	7.4	2
26	A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 759-770	3.5	2
25	A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2017 , 22, 888-e84	5.7	2
24	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).. <i>Prostate Cancer and Prostatic Diseases</i> , 2022 ,	6.2	2
23	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2020 , 47, 457-467	2.9	2
22	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer 2021 , 9,		2
21	Protein kinase inhibitors for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1889-1899	4	2
20	Abiraterone's efficacy confirmed; time to aim higher. <i>Lancet Oncology, The</i> , 2015 , 16, 119-21	21.7	1
19	Prostate cancer: Intermediate efficacy end points to assess modern therapies. <i>Nature Reviews Urology</i> , 2013 , 10, 686-7	5.5	1
18	Radium-223 in prostate cancer: emitting the right signals. <i>Lancet Oncology, The</i> , 2016 , 17, 1186-7	21.7	1
17	The Winds of Change: Emerging Therapeutics in Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 382-390	7.1	1
16	Behind the IL-8 ball in prostate cancer.. <i>Nature Cancer</i> , 2021 , 2, 775-776	15.4	1
15	Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer. <i>Oncologist</i> , 2021 , 26, 729-e1493	5.7	1
14	Lutetium-177-PSMA-617: A Vision of the Future.. <i>Cancer Biology and Therapy</i> , 2022 , 23, 186-190	4.6	1
13	Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids. <i>JAAD Case Reports</i> , 2017 , 3, 322-325	1.4	0

12	Modern immunotherapy for the treatment of prostate cancer. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2010 , 7, 37-42		0
11	A pilot study on the clinical value of 18F-sodium fluoride PET/CT in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10589-10589	2.2	0
10	Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2020 , 21, 884-887	4.6	0
9	Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment. <i>Cancer Drug Discovery and Development</i> , 2014 , 553-568	0.3	
8	Real-world experience with abiraterone. <i>Lancet Oncology, The</i> , 2014 , 15, 1188-90	21.7	
7	Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials. <i>Clinical Investigation</i> , 2013 , 3, 651-663		
6	Evolving role of chemotherapy in castration-resistant prostate cancer. <i>Clinical Practice (London, England)</i> , 2012 , 9, 301-313	3	
5	Immunotherapy for Metastatic Prostate Cancer 2022 , 131-146		
4	Cancer Immunology, Immunotherapeutics, and Vaccine Approaches 2010 , 305-319		
3	A method for assessing tumor response to therapy and more precisely guiding treatment decisions so as to improve survival.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13122-e13122	2.2	
2	Expanding the use of abiraterone in prostate cancer: Is earlier always better?. <i>Cancer Biology and Therapy</i> , 2018 , 19, 97-100	4.6	
1	Assessment of Aortoiliac Atherosclerotic Plaque on CT in Prostate Cancer Patients Undergoing Treatment.. <i>Tomography</i> , 2022 , 8, 607-616	3.1	